Relmada Therapeutics, Inc. RLMD Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s stock-based comp?
- Relmada Therapeutics, Inc. (RLMD) reported stock-based comp of $956.19K in Q1 2026.
- How has Relmada Therapeutics, Inc.'s stock-based comp changed year-over-year?
- Relmada Therapeutics, Inc.'s stock-based comp decreased by 73.2% year-over-year, from $3.57M to $956.19K.
- What is the long-term trend for Relmada Therapeutics, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Relmada Therapeutics, Inc.'s stock-based comp has grown at a -23.4% compound annual growth rate (CAGR), from $40.49M to $13.91M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.